We turn discovery into action, advancing differentiated small molecule medicines through in-house expertise and strategic partnerships. Our therapies aim to address serious conditions where patients are underserved by existing treatments.
LATEST NEWS
February 24, 2025
Tay Therapeutics Strengthens BET Asset Portfolio with Key IP Assignment from Dundee University
September 27, 2024
Tay Therapeutics announces Publication of New Patent for Readthrough Agents Targeting Genetic Diseases
June 13, 2024
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
